Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC

References

• Deng R, Iyer S, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. mAbs. 2011;3(1):61–6. doi:10.4161/mabs.3.1.13799. PMID:20962582.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8(11):1351–9. doi:10.1023/A:1015836720294. PMID:1798669.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93(1):177–85. doi:10.1002/jps.10531. PMID:14648647.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci. 2009;98(10):3850–61. doi:10.1002/jps.21682. PMID:19177515.
   PubMed Web of Science ®Google Scholar
• Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet. 2012;27(3):354–9. doi:10.2133/dmpk.DMPK-11-SH-059. PMID:22146109.
   PubMed Web of Science ®Google Scholar
• Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Pharm. Drug Dispos. 2010;31(4):253–63.
   PubMed Web of Science ®Google Scholar
• Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther. 2012;341(3):702–8. doi:10.1124/jpet.112.191999. PMID:22414855.
   PubMed Web of Science ®Google Scholar
• Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, Abraham A, Zutshi A, Lin J, Singh P. Quantitative prediction of human pharmacokinetics for mabs exhibiting target-mediated disposition. AAPS J. 2015;17(2):389–99. doi:10.1208/s12248-014-9690-8. PMID:25445845.
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies. Clin Pharmacokinet. 2011;50(2):131–42. doi:10.2165/11537430-000000000-00000. PMID:21241072.
   PubMed Web of Science ®Google Scholar
• Bender B, Leipold DD, Xu K, Shen B-Q, Tibbitts J, Friberg LE. A Mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. AAPS J. 2014;16(5):994–1008. doi:10.1208/s12248-014-9618-3. PMID:24917179.
   PubMed Web of Science ®Google Scholar
• Sukumaran S, Zhang C, Leipold DD, Saad OM, Xu K, Gadkar K, Samineni D, Wang B, Milojic-Blair M, Carrasco-Triguero M, et al. Development and translational application of an integrated, mechanistic model of antibody-drug conjugate pharmacokinetics. AAPS J. 2017;19(1):130–40. doi:10.1208/s12248-016-9993-z. PMID:27679517.
   PubMed Web of Science ®Google Scholar
• Sukumaran S, Gadkar K, Zhang C, Bhakta S, Liu L, Xu K, Raab H, Yu SF, Mai E, Fourie-O'Donohue A, et al. Mechanism-based pharmacokinetic/pharmacodynamic model for THIOMAB™ drug conjugates. Pharm Res. 2015;32(6):1884–93. doi:10.1007/s11095-014-1582-1. PMID:25446772.
   PubMed Web of Science ®Google Scholar
• Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Evolution of Antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS J. 2016;18(4):861–75. doi:10.1208/s12248-016-9904-3. PMID:27029797.
   PubMed Web of Science ®Google Scholar
• Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: A case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643–59. doi:10.1007/s10928-012-9276-y. PMID:23151991.
   PubMed Web of Science ®Google Scholar
• Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, Haddish-Berhane N, Betts A, Leal M. A Priori Prediction of tumor payload concentrations: Preclinical case study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate. AAPS J. 2014;16(3):452–63. doi:10.1208/s12248-014-9576-9. PMID:24578215.
   PubMed Web of Science ®Google Scholar
• Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody-drug conjugates: Current status and future directions. Drug Discov Today. 2014;19(7):869–81. doi:10.1016/j.drudis.2013.11.004. PMID:24239727.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29. doi:10.1146/annurev-med-050311-201823. PMID:23043493.
   PubMed Web of Science ®Google Scholar
• McCombs JR, Owen SC. Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17(2):339–51. doi:10.1208/s12248-014-9710-8. PMID:25604608.
   PubMed Web of Science ®Google Scholar
• Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34–45. doi:10.4161/mabs.27022. PMID:24423619.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotech. 2015;33(7):733–5. doi:10.1038/nbt.3212.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats. Bioconjug Chem. 2011;22(10):1994–2004. doi:10.1021/bc200212a. PMID:21913715.
   PubMed Web of Science ®Google Scholar
• Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug Conjugates. Pharm Res. 2015;32(11):3470–9. doi:10.1007/s11095-014-1584-z. PMID:25446773.
   PubMed Web of Science ®Google Scholar
• Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: A PK/PD approach. J Pharmacokinet Pharmacodyn. 2013;40(5):557–71. doi:10.1007/s10928-013-9329-x. PMID:23933716.
   PubMed Web of Science ®Google Scholar
• Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res. 2015;32(11):3508–25. doi:10.1007/s11095-015-1626-1. PMID:25666843.
   PubMed Web of Science ®Google Scholar
• Sapra P, Betts A, Boni J. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacool. 2013;6(5):541–55. doi:10.1586/17512433.2013.827405.
   PubMed Web of Science ®Google Scholar
• Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR. Preclinical to clinical translation of antibody-drug conjugates using PK/PD Modeling: A retrospective analysis of inotuzumab ozogamicin. AAPS J. 2016;18(5):1101–16. doi:10.1208/s12248-016-9929-7. PMID:27198897.
   PubMed Web of Science ®Google Scholar
• Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65–73. doi:10.1007/s11899-011-0103-0. PMID:22109628.
   PubMed Web of Science ®Google Scholar
• Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198–208. doi:10.1182/blood-2011-11-325050. PMID:22286199.
   PubMed Web of Science ®Google Scholar
• Pillow TH. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease. Pharmaceutical Patent Analyst. 2017;6(1):25–33. doi:10.4155/ppa-2016-0032. PMID:28155578.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480. PMID:18641636.
   PubMed Web of Science ®Google Scholar
• Robillard N, Fau - Wuilleme S, Wuilleme S, Fau - Lode L, Lode L, Fau - Magrangeas F, Magrangeas F, Fau - Minvielle S, Minvielle S, Fau - Avet-Loiseau H, Avet-Loiseau H. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. ( 0887-6924 (Print)).
   Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59. doi:10.1007/s00262-008-0523-4. PMID:18446337.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VHJ, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–70. doi:10.1182/blood-2006-09-047399. PMID:17227830.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705–11. doi:10.1182/blood-2011-12-398370. PMID:22378848.
   PubMed Web of Science ®Google Scholar
• Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295–302. doi:10.1182/blood-2004-07-2784. PMID:15454492.
   PubMed Web of Science ®Google Scholar
• Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, et al. Differences in CD33 Intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560–6. doi:10.1309/1WMW-CMXX-4WN4-T55U. PMID:12375643.
   PubMed Web of Science ®Google Scholar
• Bea K. First clinical results of ADCT-402, a novel pyrrolobenzodiazepine-based Antibody Drug Conjugate (ADC), in Relapsed/refractory B-cell lineage non-hodgkin lymphoma. 14th International Conference on Malignant Lymphoma (ICML); 2017.
   Google Scholar
• Horwitz SM, Fanale MA, Spira AI, et al. Interim data from the first clinical study of ADCT-30, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory hodgkin/non-hodgkin lymphoma. Hematol Oncol. 2017;35:270–1. doi:10.1002/hon.2438_143.
   Google Scholar
• Stein AS, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, et al. A phase 1 trial of SGN-CD33A As monotherapy in patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood. 2015;126(23):324.
   Google Scholar
• Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, et al. Phase III randomized multicenter study of a humanized Anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110–6. doi:10.1200/JCO.2005.09.133. PMID:15961759.
   PubMed Web of Science ®Google Scholar
• Kossman SE, Scheinberg Da, Fau - Jurcic JG, Jurcic Jg, Fau - Jimenez J, Jimenez J, Fau - Caron PC, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. ( 1078-0432 (Print)).
   Google Scholar
• Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. ( 1043-1802 (Print)).
   Google Scholar
• Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012;30(3):1121–31. doi:10.1007/s10637-011-9670-0. PMID:21519855.
   PubMed Web of Science ®Google Scholar
• Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455. doi:10.1182/blood-2013-03-491506. PMID:23770776.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. ( 1532-1681 (Electronic)).
   Google Scholar
• Chen P, Wang J, Fau - Hope K, Hope K, Fau - Jin L, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. ( 0161-5505 (Print)).
   Google Scholar
• Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial. Leukemia Lymphoma. 2009;50(8):1336–44. doi:10.1080/10428190903050013. PMID:19557623.
   PubMed Web of Science ®Google Scholar
• Chang J. Biologic therapy of leukemia. Br J Cancer. 2004;90(1):281-. doi:10.1038/sj.bjc.6601432.
   Google Scholar
• Giles F, Morariu-Zamfir R, Lambert J, et al. Phase I Study of AVE9633, an AntiCD33-Maytansinoid immunoconjugate, administered as an intravenous infusion in patients with refractory/relapsed CD33-positive acute myeloid leukemia (AML). Blood. 2006;108(11):4548.
   Web of Science ®Google Scholar
• Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacool. 2004;44(8):873–80. doi:10.1177/0091270004267595.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacool. 2001;41(11):1206–14. doi:10.1177/00912700122012751.
   PubMed Web of Science ®Google Scholar
• Heider K-H, Konopitzky R, Ostermann E, et al. A Novel Fc-Engineered Antibody to CD33 with Enhanced ADCC Activity for Treatment of AML. Blood. 2012;120(21):1363.
   Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, et al. gemtuzumab ozogamicin, a potent and selective Anti-CD33 Antibody−calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47–58. doi:10.1021/bc010021y. PMID:11792178.
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E. Target-mediated drug disposition model: Approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009;5(7):803–12. doi:10.1517/17425250902992901. PMID:19505189.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Bornstein GG, Klakamp SL. Development of antibody-based therapeutics: Translational considerations. New York: Springer; 2012.
   Google Scholar
• Bornstein GG. Antibody drug conjugates: Preclinical considerations. AAPS J. 2015;17(3):525–34. doi:10.1208/s12248-015-9738-4. PMID:25724883.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009;14(5):298–305. doi:10.1016/j.drudis.2008.12.008. PMID:19152840.
   PubMed Web of Science ®Google Scholar
• Xu S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. ( 1573-904X (Electronic)).
   Google Scholar
• Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. 2009;36(5):407. doi:10.1007/s10928-009-9129-5. PMID:19728050.
   PubMed Web of Science ®Google Scholar
• Yan X, Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2012;39(2):141–6. doi:10.1007/s10928-011-9233-1. PMID:22215144.
   PubMed Web of Science ®Google Scholar
• Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood. 2017;129(5):609. doi:10.1182/blood-2016-08-735365. PMID:27908880.
   PubMed Web of Science ®Google Scholar
• Flygare JA, Gunzner-Toste JL, Pillow T, Howard PW, Masterson L. Pyrrolobenzodiazepines and conjugates thereof. Google Patents. 2013.
   Google Scholar
• Pillow TH, Schutten M, Yu S-F, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, et al. Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers. Mol Cancer Ther. 2017. doi:10.1158/1535-7163.MCT-16-0641. PMID:28223423.
   PubMed Web of Science ®Google Scholar
• Kaur S, Liu L, Cortes DF, Shao J, Jenkins R, Mylott WR Jr, Xu K. Validation of a biotherapeutic immunoaffinity-LC-MS/MS assay in monkey serum: ‘Plug-and-play’ across seven molecules. Bioanalysis. 2016;8(15):1565–77. doi:10.4155/bio-2016-0117. PMID:27396481.
   PubMed Web of Science ®Google Scholar
• Carrasco-Triguero M, Davis H, Zhu Y, Coleman D, Nazzal D, Vu P, Kaur S. Application of a plug-and-play immunogenicity assay in cynomolgus monkey serum for ADCs at Early stages of drug development. ( 2314-7156 (Electronic)).
   Google Scholar
• Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010;37(1):25–47. doi:10.1007/s10928-009-9142-8. PMID:20012173.
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573–91. doi:10.1007/s10928-008-9102-8. PMID:19005743.
   PubMed Web of Science ®Google Scholar
• Ploeger BA, Van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet. 2009;24(1):3–15. doi:10.2133/dmpk.24.3. PMID:19252332.
   PubMed Web of Science ®Google Scholar